Adma Biologics (ADMA) Q2 Revenue Up 14%
Adma Biologics (NASDAQ:ADMA), a plasma-derived biologics manufacturer focused on immunotherapies, released its earnings for Q2 2025 on August 6, 2025. The quarter showed continued revenue growth, with GAAP total revenue of $122.0 million, with total revenue (GAAP) reaching $122.0 million, edging out analyst consensus on GAAP total revenue. Earnings per share (EPS) were $0.14 (GAAP), while Adjusted net income and adjusted EBITDA also advanced. Gross margin (GAAP) improved to 55.1%, up from 53.6% in Q2 2024. Operational achievements included the start of commercial yield enhancement in manufacturing and key steps in pipeline development, but, in line with expectations, management kept its long-term outlook unchanged for now.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Adma Biologics is a specialty pharmaceutical company that produces plasma-derived products. Its core business is transforming collected plasma into immunoglobulin therapies for people with compromised immune systems. The company's main products include immune globulin intravenous (IGIV) therapies used for treating primary immunodeficiency and other immune-related diseases.
Source Fool.com
